EDIT Valuation

Editas Medicine Inc

Add to Watchlist

Advanced Chart

4.150

+0.22(5.598%)1D

Overview
Forecast
Valuation
Earnings

EDIT Relative Valuation

EDIT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, EDIT is overvalued; if below, it's undervalued.

Historical Valuation

Editas Medicine Inc (EDIT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -5.76. The fair price of Editas Medicine Inc (EDIT) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：3.93

Fair

-3.64

Trailing

Forward

-1.35

EV/EBITDA

Editas Medicine Inc. (EDIT) has a current EV/EBITDA of -1.35. The 5-year average EV/EBITDA is -3.38. The thresholds are as follows: Strongly Undervalued below -13.26, Undervalued between -13.26 and -8.32, Fairly Valued between 1.56 and -8.32, Overvalued between 1.56 and 6.50, and Strongly Overvalued above 6.50. The current Forward EV/EBITDA of -1.35 falls within the Historic Trend Line -Fairly Valued range.

-1.83

EV/EBIT

Editas Medicine Inc. (EDIT) has a current EV/EBIT of -1.83. The 5-year average EV/EBIT is -3.24. The thresholds are as follows: Strongly Undervalued below -12.73, Undervalued between -12.73 and -7.99, Fairly Valued between 1.50 and -7.99, Overvalued between 1.50 and 6.25, and Strongly Overvalued above 6.25. The current Forward EV/EBIT of -1.83 falls within the Historic Trend Line -Fairly Valued range.

15.45

Editas Medicine Inc. (EDIT) has a current PS of 15.45. The 5-year average PS is 62.29. The thresholds are as follows: Strongly Undervalued below -69.35, Undervalued between -69.35 and -3.53, Fairly Valued between 128.12 and -3.53, Overvalued between 128.12 and 193.94, and Strongly Overvalued above 193.94. The current Forward PS of 15.45 falls within the Historic Trend Line -Fairly Valued range.

-3.64

P/OCF

Editas Medicine Inc. (EDIT) has a current P/OCF of -3.64. The 5-year average P/OCF is -6.34. The thresholds are as follows: Strongly Undervalued below -18.75, Undervalued between -18.75 and -12.54, Fairly Valued between -0.13 and -12.54, Overvalued between -0.13 and 6.07, and Strongly Overvalued above 6.07. The current Forward P/OCF of -3.64 falls within the Historic Trend Line -Fairly Valued range.

-3.82

P/FCF

Editas Medicine Inc. (EDIT) has a current P/FCF of -3.82. The 5-year average P/FCF is -6.43. The thresholds are as follows: Strongly Undervalued below -19.60, Undervalued between -19.60 and -13.02, Fairly Valued between 0.15 and -13.02, Overvalued between 0.15 and 6.73, and Strongly Overvalued above 6.73. The current Forward P/FCF of -3.82 falls within the Historic Trend Line -Fairly Valued range.

Editas Medicine Inc (EDIT) has a current Price-to-Book (P/B) ratio of 17.90. Compared to its 3-year average P/B ratio of 2.59 , the current P/B ratio is approximately 590.69% higher. Relative to its 5-year average P/B ratio of 3.31, the current P/B ratio is about 441.00% higher. Editas Medicine Inc (EDIT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of -62.42%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of -41.30% , the current FCF yield is about -100.00% lower.

18.90

P/B

Median3y

2.59

Median5y

3.31

-57.99

FCF Yield

Median3y

-62.42

Median5y

-41.30

Competitors Valuation Multiple

The average P/S ratio for EDIT's competitors is 0.00, providing a benchmark for relative valuation. Editas Medicine Inc Corp (EDIT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 597.47%, this premium appears sustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

Design Therapeutics Inc

Loss

395.22M

LXEO.O

Lexeo Therapeutics Inc

Aldeyra Therapeutics Inc

Loss

336.61M

Performance Decomposition

Market capitalization of EDIT increased by 43.10% over the past 1 year. The primary factor behind the change was an increase in Revenue Growth from 513.00K to 3.58M.

The secondary factor is the Margin Expansion, contributed -88.71%to the performance.

Overall, the performance of EDIT in the past 1 year is driven by Revenue Growth. Which is more sustainable.

597.47%

513.00K → 3.58M

Revenue Growth

-88.71%

-13.18K → -1.49K

Margin Expansion

-465.66%

0.40 → -1.46

P/E Change

43.10%